FXR
El receptor X de farnesoide (FXR) es un receptor nuclear que desempeña un papel clave en la regulación de la homeostasis de los ácidos biliares, el metabolismo de los lípidos y la regulación de la glucosa. El FXR es un objetivo terapéutico potencial para el tratamiento de enfermedades hepáticas, trastornos metabólicos y enfermedades cardiovasculares. Los inhibidores del FXR pueden modular estas vías, ofreciendo información sobre los mecanismos de las enfermedades y las estrategias terapéuticas. En CymitQuimica, ofrecemos una gama de inhibidores del FXR para apoyar su investigación en hepatología, metabolismo y desarrollo de fármacos.
Se han encontrado 68 productos para "FXR".
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
Chenodeoxycholic acid
CAS:Chenodeoxycholic acid (CDCA) is a bile acid that inhibits 11β-HSD2 with an IC50 value of 22 mM. High-Quality, Low-Cost!Fórmula:C24H40O4Pureza:99.70% - 99.93%Forma y color:White SolidPeso molecular:392.572LY2562175
CAS:LY2562175 is an effective and selective FXR agonist (EC50: 193 nM).Fórmula:C28H27Cl2N3O4Pureza:99.16% - 99.63%Forma y color:SolidPeso molecular:540.438Ursodeoxycholic acid
CAS:Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5),inhibits cholesterol absorption. High-Quality, Low-Cost!Fórmula:C24H40O4Pureza:99.48% - ≥95%Forma y color:White SolidPeso molecular:392.572dual FXR/PPARδ agonist-2
Dual FXR/PPARδ agonist-2 is a dual agonist for FXR and PPARδ, derived from the hybridization of the FXR agonist GW-4064 and the PPARδ agonist GW-0742. It exhibits potent dual-target activity, with an EC50 of 12.28 nM for FXR activation and a 69% activation rate of PPARδ at a concentration of 100 nM. Additionally, dual FXR/PPARδ agonist-2 demonstrates antifibrotic effects in a mouse model of pulmonary fibrosis.LZ-007
CAS:LZ-007 is an agonist of the Farnesoid X receptor (FXR), with an EC50 of 51 nM as determined by TR-FRET assay, and an EC50 of 76 nM in HepG2 cells. It exhibits favorable pharmacokinetic properties in SD rats and can improve metabolic dysfunction-associated steatohepatitis induced by high-fat diets and CCl4 in mice.Fórmula:C27H29F3N2O5Forma y color:SolidPeso molecular:518.53F44-A13
CAS:F44-A13 is an orally active, highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. It optimizes cholesterol metabolism and reduces activity by inducing CYP7A1 expression, lowering cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) levels in mouse models. F44-A13 is applicable for studying metabolic diseases associated with lipid disorders [1].Fórmula:C28H40N4O5SForma y color:SolidPeso molecular:544.71Linafexor
CAS:Linafexor, Non-steroidal FXR agonist, for primary sclerosing cholangitis (PSC) and non-alcoholic steatohepatitis (NASH).Fórmula:C28H25Cl2FN4O4Pureza:99.76%Peso molecular:571.43Nuclear Receptor Compound Library
A unique collection of xnum nuclear receptor signaling targeted compounds for high throughput and high content screening;Forma y color:Odour SolidFXR agonist 10
FXR agonist10 (Compound 27) acts as an agonist for FXR with an EC50 of 14.26 μM. It increases the expression of SHP and BSEP proteins while decreasing the expression of NTCP and CYP7A1 proteins. Additionally, FXR agonist10 has been shown to ameliorate ANIT-induced cholestasis in mouse models.Fórmula:C15H22O4Forma y color:SolidPeso molecular:266.33FXR agonist 5
CAS:FXR agonist 5 is an FXR agonist used in the study of liver diseases or diseases mediated by metabolic inflammation.Fórmula:C40H53N5O5Pureza:99.74%Forma y color:White SolidPeso molecular:683.88LH10
LH10 is an FXR agonist based on fexaramine, with an EC50 of 0.14 μM. It offers hepatoprotective effects, mitigating conditions such as cholestasis induced by alpha naphthylisothiocyanate (ANIT), acute liver injury caused by APAP, and non-alcoholic steatohepatitis (NASH).Fórmula:C34H33N3O2Forma y color:SolidPeso molecular:515.64ZLY28
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1.Fórmula:C29H23Cl2NO4Pureza:98%Forma y color:SolidPeso molecular:520.4Tauro-obeticholic acid-d4
Tauro-obeticholic acid-d4 is the deuterium-labeled form of Tauro-obeticholic acid. Tauro-obeticholic acid functions as the active metabolite of taurine. Obeticholic acid is an orally bioavailable farnesoid X receptor (FXR) agonist.FXR/TGR5 agonist 1
CAS:FXR/TGR5 agonist 1 acts as an agonist on both FXR and TGR5 receptors and is utilized for treating fatty liver disease.Fórmula:C31H32ClN3O3Forma y color:SolidPeso molecular:530.07Fexarene
CAS:Fexarene is a non-steroidal FXR agonist.Fórmula:C32H33NO3Pureza:98%Forma y color:SolidPeso molecular:479.62Tauro-β-muricholic acid sodium
CAS:Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM).Fórmula:C26H44NNaO7SPureza:98%Forma y color:SolidPeso molecular:537.69NR1H4 Protein, Human, Recombinant (His)
NR1H4 Protein, Human, Recombinant (His) is expressed in E.Forma y color:Lyophilized PowderPeso molecular:27.83 kDa (predicted)NR1H4 Protein, Mouse, Recombinant (His)
NR1H4 Protein, Mouse, Recombinant (His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 27.80 kDa.Forma y color:Lyophilized PowderPeso molecular:27.80 kDa (predicted)Isochenodeoxycholic Acid-D4
Isochenodeoxycholic Acid-D4 is a deuterated derivative of Isochenodeoxycholic Acid. Isochenodeoxycholic Acid-D4 is a deuterated derivative of isochenodeoxycholic acid used for FXR signaling and 3β-dehydrogenation metabolism research.Fórmula:C24H36D4O4Peso molecular:396.6FXR agonist 3
FXR agonist 3 is an anti NASH compound with anti-fibrotic and active properties that inhibits the expression of COL1A1, TGF-β1, α-SMA and TIMP1.Fórmula:C28H28BrNO4Pureza:95.04%Forma y color:Yellow SolidPeso molecular:521.12
